Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Asset Writedowns and Impairment: 2009-2024

Historic Asset Writedowns and Impairment for Myriad Genetics (MYGN) over the last 9 years, with Dec 2024 value amounting to $43.0 million.

  • Myriad Genetics' Asset Writedowns and Impairment was N/A to $43.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $56.6 million, marking a year-over-year change of. This contributed to the annual value of $56.6 million for FY2024, which is N/A change from last year.
  • As of Q4 2024, Myriad Genetics' Asset Writedowns and Impairment stood at $43.0 million, which was up 5,275.00% from $800,000 recorded in Q3 2024.
  • Myriad Genetics' 5-year Asset Writedowns and Impairment high stood at $98.4 million for Q1 2020, and its period low was $800,000 during Q3 2024.
  • For the 2-year period, Myriad Genetics' Asset Writedowns and Impairment averaged around $12.2 million, with its median value being $8.4 million (2022).